PRA Health Sciences (PRAH) Lowered to “Buy” at BidaskClub

BidaskClub lowered shares of PRA Health Sciences (NASDAQ:PRAH) from a strong-buy rating to a buy rating in a research note released on Friday morning.

A number of other analysts have also recently commented on PRAH. SunTrust Banks boosted their price target on PRA Health Sciences to $120.00 and gave the stock a buy rating in a research report on Monday, November 5th. Robert W. Baird boosted their price target on PRA Health Sciences from $112.00 to $116.00 and gave the stock an outperform rating in a research report on Tuesday, September 11th. Evercore ISI began coverage on PRA Health Sciences in a research report on Thursday, October 4th. They issued an inline rating and a $120.00 price target on the stock. Finally, UBS Group began coverage on PRA Health Sciences in a research report on Tuesday, October 9th. They issued a neutral rating on the stock. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $111.50.

Shares of PRAH traded down $3.27 during mid-day trading on Friday, reaching $103.07. The company had a trading volume of 390,643 shares, compared to its average volume of 545,900. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 1.22. PRA Health Sciences has a 52 week low of $79.20 and a 52 week high of $121.98. The stock has a market cap of $6.91 billion, a P/E ratio of 32.21, a P/E/G ratio of 1.54 and a beta of 0.77.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, October 31st. The medical research company reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.06. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The firm had revenue of $717.60 million for the quarter, compared to analysts’ expectations of $729.63 million. During the same period in the previous year, the firm posted $0.88 EPS. The business’s revenue for the quarter was up 23.3% compared to the same quarter last year. On average, equities analysts anticipate that PRA Health Sciences will post 3.93 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in PRA Health Sciences by 11.9% in the 3rd quarter. BlackRock Inc. now owns 6,074,310 shares of the medical research company’s stock valued at $669,328,000 after acquiring an additional 647,401 shares in the last quarter. Vanguard Group Inc. lifted its position in PRA Health Sciences by 12.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,811,972 shares of the medical research company’s stock valued at $640,421,000 after acquiring an additional 658,191 shares in the last quarter. Bank of New York Mellon Corp lifted its position in PRA Health Sciences by 12.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,465,247 shares of the medical research company’s stock valued at $271,645,000 after acquiring an additional 268,243 shares in the last quarter. FMR LLC lifted its position in PRA Health Sciences by 1.0% in the 3rd quarter. FMR LLC now owns 2,317,493 shares of the medical research company’s stock valued at $255,365,000 after acquiring an additional 21,818 shares in the last quarter. Finally, Eagle Asset Management Inc. lifted its position in PRA Health Sciences by 3.9% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,074,402 shares of the medical research company’s stock valued at $118,388,000 after acquiring an additional 39,839 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: Reverse Stock Split

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply